CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.51B, above the global median of $1.15B
- FinancialsAltman Z-Score 4.11: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.51BUSDvs all stocks (USD)
Revenue (TTM)
72.25MUSDvs all stocks (USD)
Profit Margin
-49.88%vs Biotechnology peers
52-Week Change
171.33%vs all stocks
Market Capitalization
1.51BUSDvs all stocks (USD)
Enterprise Value
1.18BUSDvs all stocks (USD)
Forward P/E
-12.56xvs Biotechnology peers
Price to Sales (TTM)
20.84xvs Biotechnology peers
Price to Book (MRQ)
3.96xvs Biotechnology peers
Enterprise to Revenue
16.35xvs Biotechnology peers
Enterprise to EBITDA
-17.75xvs Biotechnology peers
Profit Margin
-49.88%vs Biotechnology peers
Operating Margin
-50.14%vs Biotechnology peers
Return on Assets (TTM)
-8.49%vs Biotechnology peers
Return on Equity (TTM)
-9.26%vs Biotechnology peers
Revenue (TTM)
72.25MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.63USDUpdated Jul 19, 2026Quarterly Revenue Growth
12011.00%vs Biotechnology peers
Gross Profit (TTM)
72.25MUSDvs all stocks (USD)
EBITDA (TTM)
-66.56MUSDvs all stocks (USD)
Net Income (TTM)
-36.04MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
12010.96%vs Biotechnology peers
Operating Cash Flow (TTM)
107.90MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
24.01MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
45.95MUSDFY2025 · Dec 31, 2025Operating Income
-80.80MUSDvs all stocks (USD)
Pre-tax Income
-48.87MUSDFY2025 · Dec 31, 2025Income Tax Expense
12.00KUSDFY2025 · Dec 31, 2025Net Income
-48.88MUSDFY2025 · Dec 31, 2025EBIT
-80.80MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-91.69MUSDFY2025 · Dec 31, 2025Research & Development
97.58MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
29.16MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
19.53MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-48.88MUSDFY2025 · Dec 31, 2025Operating Cash Flow
125.56MUSDFY2025 · Dec 31, 2025Free Cash Flow
125.04MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
121.63MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-48.88MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.60MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
0.00USDFY2025 · Dec 31, 2025Stock-based Compensation
8.48MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.16MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.19MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.60MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
165.78MUSDFY2025 · Dec 31, 2025Capital Expenditures
-518.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-450.95MUSDFY2025 · Dec 31, 2025Sale of Investments
209.62MUSDFY2025 · Dec 31, 2025Other Investing Activity
12.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-229.35MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-1.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
44.92MSharesUpdated Jul 19, 2026Float Shares
23.12MSharesUpdated Jul 19, 2026Shares Short
3.15MSharesUpdated Jul 19, 2026Short Ratio
6.72daysvs all stocks
Short % of Shares Outstanding
13.82%vs all stocks
% Held by Insiders
3.17%vs all stocks
% Held by Institutions
102.62%vs all stocks
Total Cash (MRQ)
347.40MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.71USDUpdated Jul 19, 2026Total Debt (MRQ)
23.09MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0610xvs Biotechnology peers
Current Ratio (MRQ)
4.71xvs Biotechnology peers
Book Value per Share (MRQ)
8.43USDUpdated Jul 19, 2026Total Assets
596.19MUSDvs all stocks (USD)
Total Current Assets
410.96MUSDFY2025 · Dec 31, 2025Total Liabilities
214.26MUSDFY2025 · Dec 31, 2025Total Non-current Assets
185.22MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
127.33MUSDFY2025 · Dec 31, 2025Total Current Liabilities
86.93MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
120.72MUSDFY2025 · Dec 31, 2025Other Short-term Investments
270.37MUSDFY2025 · Dec 31, 2025Accounts Receivable
10.36MUSDFY2025 · Dec 31, 2025Accounts Payable
10.28MUSDFY2025 · Dec 31, 2025Short-term Debt
2.21MUSDFY2025 · Dec 31, 2025Deferred Revenue
62.27MUSDFY2025 · Dec 31, 2025Other Current Liabilities
148.00KUSDFY2025 · Dec 31, 2025Long-term Debt
21.41MUSDFY2025 · Dec 31, 2025Common Stock (Book)
45.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-167.25MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
381.93MUSDvs all stocks (USD)
52-Week Low
10.62USDUpdated Jul 19, 202652-Week High
38.04USDUpdated Jul 19, 202652-Week Change
171.33%vs all stocks
50-Day MA
31.63USDUpdated Jul 19, 2026200-Day MA
26.63USDUpdated Jul 19, 2026Avg 10-Day Volume
574.73KSharesUpdated Jul 19, 2026Avg 30-Day Volume
509.15KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.8000USDUpdated Jul 19, 2026Other Income / Expense
12.40MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.11: safe zoneNotable
Altman Z-Score: 4.11
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.51B, above the global median of $1.15BNotable
Market cap (USD): 1,505,522,802Global Median: 1,146,734,693.424
Levered free cash flow is $24.01M, above the global median of $16.24MNotable
Levered free cash flow (USD): 24,014,124Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Mayinglong Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pacific Shuanglin Bio-Pharmacy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Olix Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhejiang Jolly Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Integra LifeSciences Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xeris Biopharma Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Marksans Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tianjin Chase Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Concord Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Amadeus IT Group S.A.
3 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables Growing
Safran SA
3 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables Growing
Coloplast A/S Class B
3 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables Growing